NEOS Investment Management LLC Has $64.06 Million Holdings in Gilead Sciences, Inc. $GILD

NEOS Investment Management LLC raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 59.6% during the third quarter, according to its most recent filing with the SEC. The firm owned 577,119 shares of the biopharmaceutical company’s stock after purchasing an additional 215,619 shares during the period. NEOS Investment Management LLC’s holdings in Gilead Sciences were worth $64,060,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of GILD. GoalVest Advisory LLC lifted its holdings in Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares during the period. Corundum Trust Company INC bought a new position in shares of Gilead Sciences in the 3rd quarter worth about $26,000. Howard Hughes Medical Institute acquired a new position in shares of Gilead Sciences in the 2nd quarter valued at about $30,000. Putney Financial Group LLC boosted its position in shares of Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 94 shares in the last quarter. Finally, MTM Investment Management LLC grew its stake in Gilead Sciences by 176.0% during the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 176 shares during the period. 83.67% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CEO Daniel Patrick O’day sold 115,640 shares of Gilead Sciences stock in a transaction that occurred on Friday, January 23rd. The stock was sold at an average price of $135.00, for a total transaction of $15,611,400.00. Following the transaction, the chief executive officer owned 566,698 shares of the company’s stock, valued at $76,504,230. The trade was a 16.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction on Friday, November 28th. The shares were sold at an average price of $125.08, for a total value of $625,400.00. Following the completion of the sale, the director directly owned 8,920 shares of the company’s stock, valued at $1,115,713.60. The trade was a 35.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 288,891 shares of company stock worth $40,303,946 over the last three months. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Performance

GILD opened at $154.98 on Tuesday. Gilead Sciences, Inc. has a 1-year low of $93.37 and a 1-year high of $157.29. The company has a market cap of $192.28 billion, a price-to-earnings ratio of 22.89, a PEG ratio of 2.06 and a beta of 0.36. The company’s fifty day moving average price is $130.94 and its two-hundred day moving average price is $122.68. The company has a current ratio of 1.68, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The company had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. During the same period in the previous year, the firm posted $1.90 earnings per share. The firm’s revenue for the quarter was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.1%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Friday, March 13th. Gilead Sciences’s dividend payout ratio (DPR) is currently 46.68%.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on GILD shares. TD Cowen boosted their price target on Gilead Sciences from $145.00 to $160.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. Morgan Stanley boosted their target price on shares of Gilead Sciences from $150.00 to $171.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Wolfe Research increased their target price on shares of Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a research note on Thursday, February 12th. Truist Financial lifted their price target on shares of Gilead Sciences from $145.00 to $152.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. Finally, Wells Fargo & Company increased their price objective on shares of Gilead Sciences from $150.00 to $165.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Twenty-three research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $152.50.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.